Table 1.
Characteristic | Coformulation | Pre-mixed preparation |
---|---|---|
Definition | Formulation of two separate components, which maintain distinct identity | Mixture of two components, which are unable to maintain distinct identity |
Appearance | Clear | Cloudy |
Proportion | Pre-determined | Pre-determined |
Pharmacokinetics/pharmacodynamics | Both components maintain distinct PK/PD profiles | PK/PD profile of both components may merge |
Efficacy | Both components achieve efficacy at targeted endpoint | Both components often achieve targeted end points |
Scope | Allows coformulation of separate classes of drugs | Does not allow mixing of different classes of drugs |
Examples | Insulin degludec + insulin aspart; insulin degludec + liraglutide; insulin glargine + lixisenatide | Biphasic human insulin; biphasic insulin aspart; biphasic insulin lispro |
PD pharmacodynamics, PK pharmacokinetics